Researcher
Karen Vanhoorelbeke
- Disciplines:Biochemistry and metabolism, Cardiac and vascular medicine, Medical biochemistry and metabolism
Affiliations
- Chemistry, Kulak Kortrijk Campus (Department)
Responsible
From1 Oct 2018 → Today - Chemistry, Kulak Kortrijk Campus (Department)
Member
From1 Jan 2009 → Today - Faculty of Medicine (Faculty)
Member
From1 Oct 2004 → 30 Sep 2006 - Faculty of Science, Kulak Kortrijk Campus (Faculty)
Member
From1 Oct 2000 → 31 Dec 2008
Projects
1 - 10 of 58
- B-specific: B-cell related gene and protein markers with prognostic and therapeutic value for CVDFrom1 Oct 2023 → TodayFunding: Horizon Europe - European Innovation Council (EIC)
- A novel targeted therapy to treat bleeding in patients with a left ventricular assist device.From1 May 2023 → TodayFunding: IOF - mandates
- Universal Chimeric Antigen Receptor (UniCAR) T-cell therapy: an innovative treatment for autoimmune diseaseFrom5 Apr 2023 → TodayFunding: Own budget, for example: patrimony, inscription fees, gifts
- Universal chimeric antigen receptor (uniCAR)-T cell therapy to treat autoimmune diseases: immune mediated thrombotic thrombocytopenic purpura as a model system.From1 Mar 2023 → TodayFunding: Own budget, for example: patrimony, inscription fees, gifts
- Flow cytometer for the Interdisciplinary Research Facility Life Sciences at Campus Kulak KortrijkFrom1 Jan 2023 → TodayFunding: BOF - scientific equipment program
- Allosteric ADAMTS13 activation: elucidating long-range structural crosstalk bringing the enzyme in a preactivated stateFrom1 Jan 2023 → TodayFunding: FWO research project (including WEAVE projects)
- An integrated approach to restore tolerance in autoimmune diseaseFrom1 Oct 2022 → TodayFunding: HORIZON.1.2 - Marie Skłodowska-Curie-actions (MSCA)
- Next-generation DNA vectors to improve efficacy, precision and accessibility of antibody gene transferFrom15 Mar 2022 → 14 Mar 2024Funding: BOF - various
- Innovative approaches to tackle autoimmune diseases: immune-mediated thrombotic thrombocytopenic purpura as a disease modelFrom1 Jul 2021 → 30 Jun 2023Funding: BOF - various
- A novel biomarker to improve the quality of life of immune mediatied thrombotic thrombocytopenic purpura patients.From1 Jun 2021 → 31 May 2023Funding: Foreign foundations, funds with scientific view
Publications
41 - 50 of 210
- Tuning the Surface Interactions between Single Cells and an OSTE+ Microwell Array for Enhanced Single Cell Manipulation(2021)
Authors: Jolien Breukers, Sara Horta, Caroline Struyfs, Dragana Spasic, Nick Geukens, Karin Thevissen, Bruno Cammue, Karen Vanhoorelbeke, Jeroen Lammertyn
Pages: 2316 - 2326 - Tuning the Surface Interactions between Single Cells and an OSTE plus Microwell Array for Enhanced Single Cell Manipulation(2021)
Authors: Jolien Breukers, Sara Horta, Caroline Struyfs, Dragana Spasic, Nick Geukens, Karin Thevissen, Bruno Cammue, Karen Vanhoorelbeke, Jeroen Lammertyn
Pages: 2316 - 2326 - Thrombotic thrombocytopenic purpura: from patients literacy to immunoprofiling(2020)
Authors: Leydi Carolina Velásquez Pereira, Karen Vanhoorelbeke, Simon De Meyer
- Modifying ADAMTS13 to modulate binding of pathogenic autoantibodies of patients with acquired thrombotic thrombocytopenic purpura.(2020)
Authors: Kadri Kangro, Karen Vanhoorelbeke
Pages: 2619 - 2630 - Inhibition of adamts13: a novel therapy to treat mechanical circulatory support-induced acquired von willebrand syndrome(2020)
Authors: Shannen Deconinck, Bart Meyns, Simon De Meyer, Karen Vanhoorelbeke
Pages: 3836 - 3836 - An optical tweezers integrated microfluidic platform for the identification and retrieval of antigen-specific B cells(2020)
Authors: Jolien Breukers, Karen Vanhoorelbeke, Jeroen Lammertyn
- Co(III)-NTA Mediated Antigen Immobilization on a Fiber Optic-SPR Biosensor for Detection of Autoantibodies in Autoimmune Diseases: Application in Immune-Mediated Thrombotic Thrombocytopenic Purpura(2020)
Authors: Sara Horta, Charlotte Dekimpe, Quintijn Bonnez, Filip Delport, Nick Geukens, Jeroen Lammertyn, Karen Vanhoorelbeke
Pages: 13880 - 13887 - von Willebrand factor increases in experimental cerebral malaria but is not essential for late-stage pathogenesis in mice(2020)
Authors: Sirima Kraisin, Kim Martinod, Hans Deckmyn, Karen Vanhoorelbeke, Philippe Van den Steen, Simon De Meyer
Pages: 2377 - 2390 - Insights into ADAMTS13 structure: impact on thrombotic thrombocytopenic purpura diagnosis and management(2020)
Authors: Elien Roose, Karen Vanhoorelbeke
Pages: 320 - 326 - Understanding the Health Literacy in Patients With Thrombotic Thrombocytopenic Purpura(2020)
Authors: Leydi Carolina Velásquez Pereira, Kadri Kangro, Karen Vanhoorelbeke
Patents
1 - 9 of 9
- Haemorrhagic disorder due to ventricular assist device (Inventor)
- Humanised adamts13 binding antibodies (Inventor)
- Screening and sorting of single cells (Inventor)
- Anti adamts13 antibodies and their use for treatment or prevention of haemorrhagic disorders due to ventricular assist device (Inventor)
- Humanised adamts13 binding antibodies (Inventor)
- Screening and sorting of single cells (Inventor)
- Haemorrhagic disorder due to ventricular assist device (Inventor)
- Humanised adamts13 binding antibodies (Inventor)
- Anti adamts13 antibodies and their use for treatment or prevention of haemorrhagic disorders due to ventricular assist device (Inventor)